The Effects of the Prescription Drug User Fee Act and the Food and Drug Administration Modernization Act on the Development and Approval of Therapeutic Medicines

Abstract

The Prescription Drug User Fee Act of 1992 and the Food and Drug Administration Modernization Act of 1997 include provisions that were intended to increase the efficiency of the processes required for the clinical development and regulatory review of therapeutic medicines. The expected effects of the legislative acts were decreases in the time required for clinical development and product approval. Results from the analysis of the clinical (Investigational New Drug filing date to Biologic License Application [BLA]/New Drug Application [NDA] submission date) and approval (BLA/NDA submission date to approval date) phases for 54 applications for new biopharmaceutical products submitted to the Food and Drug Administration during fiscal years 1981 through 1998 indicate that while clinical phases consistently increased, the rate of increase slowed substantially for fiscal years 1997 through 1998. The approval phase for fiscal years 1997 through 1998, however, proved to be the shortest of any time period examined. Taken together, the data from fiscal years 1997 through 1998 show the first decrease in the mean total length of time required for clinical development and approval of biopharmaceuticals. Similar analyses of data for 384 applications for new chemical entities indicate that mean clinical and approval phase lengths were shorter for fiscal years 1997 through 1998 than for any other time period included in the study. The results of this study suggest that the regulatory reforms associated with enactment of PDUFA and FDAMA have had a marked effect on the development and approval of therapeutic medicines.

Keywords

Prescription Drug User Fee Act Food and Drug Administration Modernization Act Biopharmaceutical Drug development Regulatory review

Get full access to this article

View all access options for this article.

References

Prescription Drug User Fee Act of 1992. US Public Law 102–571 (1992 Oct 29); 21 USC 379; 106 Stat 4491.

Food and Drug Administration Modernization Act of 1997. US Public Law 105–115 (1997 Nov 21); 21 USC 355a; 111 Stat 2296.

Shulman

Kaitin

The Prescription Drug User Fee Act of 1992: a five-year experiment for industry and the FDA. Pharmacoeconomics. 1996 Feb;9(2): 121–133.

Kuhlik

The US Food and Drug Administration Modernization Act of 1997 (Part one). Bio-Science Law Review. 1997;4:127–140.

Progress in achieving the performance goals referenced in the Prescription Drug User Fee Act of 1992. First Report to Congress for the Period September 1, 1992 through September 30, 1993. Rockville, MD: US Food and Drug Administration; April 1994.

Second annual performance report: Prescription Drug User Fee Act of 1992. Fiscal Year 1994 Performance Report to Congress. Rockville, MD: US Food and Drug Administration; Dec 1994.

Third annual performance report: Prescription Drug User Fee Act of 1992. Fiscal Year 1995 Performance Report to Congress. Rockville, MD: US Food and Drug Administration; Dec 1995.

Fourth annual performance report: Prescription Drug User Fee Act of 1992. FY 1996 Performance Report to Congress. Rockville, MD: US Food and Drug Administration; Dec 1996.

Final performance report: Prescription Drug User Fee Act of 1992. Fiscal Year 1997 Report to Congress. Rockville, MD: Food and Drug Administration; Dec 1997.

10.

FY 1998 performance report to Congress for the Prescription Drug User Fee Act of 1992 as amended by the Food and Drug Administration Modernization Act of 1997. www.fda.gov/ope.

11.

FY 1999 performance report to Congress for the Prescription Drug User Fee Act of 1992 as reauthorized and amended by the Food and Drug Administration Modernization Act of 1997. www.fda.gov/ope.